secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monopar Therapeutics (MNPR)
CIK:        0001645469
Form:       8-K
Filed at:   2024-04-16T23:59:59+00:00
Accession:  0001437749-24-012131
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monopar files provisional patent for MNPR-101 radiopharma optimization findings
-------------------------------------------------------------------------------

- Filed provisional patent 'Antibody Radioisotope Constructs' covering MNPR-101-Zr construct, including radioisotope, linker, and antibody variations.
- Patent aims to protect stability and biodistribution properties of MNPR-101-Zr.
- MNPR-101-Zr is a zirconium-89 imaging version of Monopar's anti-uPAR antibody for advanced cancers.
- Filing strengthens IP for MNPR-101 radiopharma program; Phase 1 dosimetry trial recently initiated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645469/000143774924012131/0001437749-24-012131-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645469/000143774924012131/mnpr20240415_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-012131

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer